The present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to collapsible prosthetic heart valves having improved mechanisms to seal against paravalvular leak.
Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.
Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve must first be collapsed or crimped to reduce its circumferential size.
When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon-expandable valves, this generally involves releasing the valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.
Clinical success of a self-expanding valve may be at least partially dependent on accurate deployment and sealing. For example, inaccurate deployment and anchoring may result in the leakage of blood between the implanted heart valve and the native valve annulus, commonly referred to as perivalvular or paravalvular leakage (“PV leak”). In aortic valves, this leakage enables blood to flow from the aorta back into the left ventricle, reducing cardiac efficiency and putting a greater strain on the heart muscle. Additionally, calcification of the aortic valve may affect performance and the interaction between the implanted valve and the calcified tissue is believed to be relevant to leakage. Additionally, in certain procedures, collapsible valves may be implanted in a native valve annulus without first resecting the native valve leaflets.
One aspect of the present disclosure relates to mechanisms and features for prosthetic valves to facilitate sealing against paravalvular leaks. These mechanisms may include, for example, patches or other types of material that expand or billow open upon PV leak to create a better seal between the prosthetic valve and the native tissue in which the prosthetic valve is implanted.
In one embodiment of the disclosure, a prosthetic heart valve includes a stent body including a generally tubular annulus section defining a first circumferential row of cells. The prosthetic heart valve may include one or more prosthetic valve elements mounted to the stent body and operative to allow flow in an antegrade direction but to substantially block flow in a retrograde direction through the annulus section. The prosthetic heart valve may further include a cuff attached to the stent body and positioned on a luminal surface of the stent body. At least one sealing member may be attached to the cuff, the at least one sealing member having an open side facing in a first axial direction and a closed side facing in a second axial direction opposite to the first axial direction so that a flow of blood in the second axial direction will tend to force blood into the at least one sealing member and cause the sealing member to billow outwardly relative to the stent body. The at least one sealing member may have a shape chosen from the group consisting of generally triangular, generally trapezoidal, and generally semicircular.
In another embodiment of the disclosure, a prosthetic heart valve includes a stent body including a generally tubular annulus section defining a first circumferential row of cells and a second circumferential row of cells distal to the first circumferential row of cells. The prosthetic heart valve may also include one or more prosthetic valve elements mounted to the stent body and operative to allow flow in an antegrade direction but to substantially block flow in a retrograde direction through the annulus section. The prosthetic heart valve my further include a cuff attached to the stent body and positioned on a luminal surface of the stent body. At least one proximal sealing member may be attached to the cuff and positioned substantially within a cell in the first circumferential row of cells, the proximal sealing member having an open side facing in a first axial direction and a closed side facing in a second axial direction opposite the first axial direction so that a flow of blood in the second axial direction will tend to force blood into the proximal sealing member and cause the proximal sealing member to billow outwardly relative to the stent body. At least one distal sealing member may be attached to the cuff and positioned substantially within a cell in the second circumferential row of cells, the distal sealing member having an open side facing in the first axial direction and a closed side facing in the second axial direction so that the flow of blood in the second axial direction will tend to force blood into the distal sealing member and cause the distal sealing member to billow outwardly relative to the stent body.
In yet a further embodiment of the disclosure, a prosthetic heart valve includes a stent body including a generally tubular annulus section and one or more prosthetic valve elements mounted to the stent body and operative to allow flow in an antegrade direction but to substantially block flow in a retrograde direction through the annulus section. A cuff may be attached to the stent body and positioned on a luminal surface of the stent body. A sealing member may be attached to the cuff, the sealing member being generally rectangular and having an open side facing in a first axial direction and a closed side facing in a second axial direction opposite to the first axial direction so that a flow of blood in the second axial direction will tend to force blood into the sealing member and cause the sealing member to billow outwardly relative to the stent body. The sealing member may be wrapped around an entire circumference of the stent body and define a pocket divided into a plurality of regions, each of the regions being in fluid communication with adjacent ones of the regions.
In still a further embodiment of the disclosure, a prosthetic heart valve includes a stent body including a generally tubular annulus section, and one or more prosthetic valve elements mounted to the stent body and operative to allow flow in an antegrade direction but to substantially block flow in a retrograde direction through the annulus section. A cuff may be attached to the stent body and positioned on a luminal surface of the stent body. At least one strut may form a finger at a proximal end thereof. The finger may be configured to lie substantially parallel to the stent body when the stent body is in a collapsed condition and may be configured to curve radially outwardly and distally when the stent body is in an expanded condition, the cuff being attached to the finger.
In a further embodiment of the disclosure, a prosthetic heart valve includes a collapsible and expandable stent body including a generally tubular annulus section and one or more prosthetic valve elements mounted to the stent body and operative to allow flow in an antegrade direction but to substantially block flow in a retrograde direction through the annulus section. A cuff may be attached to the stent body. A first sealing member is attached to the cuff, the first sealing member extending circumferentially around an abluminal surface of the stent body and having an open side facing in a first axial direction and a closed side facing in a second axial direction opposite to the first axial direction so that a flow of blood in the second axial direction will tend to force blood into the first sealing member and cause the first sealing member to billow outwardly relative to the stent body. A second sealing member is attached to the cuff, the second sealing member extending circumferentially around the abluminal surface of the stent body and having an open side facing in the first axial direction and a closed side facing in the second axial direction so that the flow of blood in the second axial direction will tend to force blood into the second sealing member and cause the second sealing member to billow outwardly relative to the stent body. The first sealing member may define a first pocket having a plurality of first regions, each of the first regions being in fluid communication with adjacent ones of the first regions. Similarly, the second sealing member may define a second pocket having a plurality of second regions, each of the second regions being in fluid communication with adjacent ones of the second regions. The first sealing member and/or the second sealing member may be wrapped around an entire circumference of the stent body. The open side of the first sealing member and/or the open side of the second sealing member may be attached to the cuff at spaced locations around a circumference of the stent body. The open side of the first sealing member may include a first plurality of openings and the open side of the second sealing members may include a second plurality of openings, the first plurality of openings being offset in a circumferential direction from the second plurality of openings. The first sealing member may be positioned nearer an inflow end of the stent body than the second sealing member. The open side of the first sealing member may be axially spaced apart from the closed side of the second sealing member. The first sealing member may comprise an extension of the cuff, the extension being wrapped around an inflow end of the stent body such that the extension is positioned on an abluminal surface of the stent body. A proximal portion of the extension on the abluminal surface of the stent body may be connected to a proximal portion of the cuff on the luminal surface of the stent body with a seam. The first sealing member and/or the second sealing member may be formed from a separate piece of material from the cuff. The first sealing member and/or the second sealing member may be formed of a single piece of material or a plurality of pieces of material. The first sealing member and/or the second sealing member may be substantially rectangular.
Various embodiments of the present disclosure will now be described with reference to the appended drawings. It is to be appreciated that these drawings depict only some embodiments of the heart valve according to the descriptions herein and are therefore not to be considered limiting of the scope of the present disclosure.
As used herein, the term “proximal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve closest to the heart when the heart valve is implanted in a patient, whereas the term “distal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve farthest from the heart when the heart valve is implanted in a patient. The term “circumferential,” when used in connection with a prosthetic heart valve, refers to the direction around the perimeter of the valve. Also, when used herein, the words “generally” and “substantially” are intended to mean that slight variations from absolute are included within the scope of the structure or process recited.
Prosthetic heart valve 100 will be described in more detail with reference to
Stent 102 may include one or more retaining elements 118 at distal end 132 thereof, the retaining elements being sized and shaped to cooperate with retaining structures provided on the deployment device (not shown). The engagement of retaining elements 118 with retaining structures on the deployment device helps maintain prosthetic heart valve 100 in assembled relationship with the deployment device, minimizes longitudinal movement of the prosthetic heart valve relative to the deployment device during unsheathing or resheathing procedures, and helps prevent rotation of the prosthetic heart valve relative to the deployment device as the deployment device is advanced to the target location and the heart valve deployed. In some variations, retaining elements 118 may be disposed near proximal end 130 of heart valve 100.
Prosthetic heart valve 100 includes one or more prosthetic valve elements, such as valve assembly 104, preferably positioned in the annulus section 140 of stent 102 and secured to the stent. Valve assembly 104 includes cuff 106 and a plurality of leaflets 108, which collectively function as a one-way valve by coapting with one another, generally allowing blood to flow in an antegrade direction while substantially blocking blood from flowing in a retrograde direction. As a prosthetic aortic valve, valve 100 has three leaflets 108. However, it will be appreciated that other prosthetic heart valves with which the active sealing mechanisms of the present disclosure may be used may have a greater or lesser number of leaflets.
Although cuff 106 is shown in
Leaflets 108 may be attached along their belly portions to cells 112 of stent 102, with the commissure between adjacent leaflets attached to commissure attachment features (“CAFs”) 116. The particular size and shape of CAFs 116 may vary in different valves, for example valves with larger or smaller diameters may include CAFs that are sized or shaped differently than the illustrated CAFs. As can be seen in
Prosthetic heart valve 100 may be used to replace, for example, a native aortic valve, a surgical heart valve, a repair device or a heart valve that has undergone a surgical procedure. The prosthetic heart valve may be delivered to the desired site (e.g., near the native aortic annulus) using any suitable delivery device. During delivery, the prosthetic heart valve is disposed inside the delivery device in the collapsed condition. The delivery device may be introduced into a patient using a transfemoral, transapical, transseptal, transaortic, subclavian or any other percutaneous approach. Once the delivery device has reached the target site, the user may deploy prosthetic heart valve 100. Upon deployment, prosthetic heart valve 100 expands so that annulus section 140 is in secure engagement within the native aortic annulus. When the prosthetic heart valve is properly positioned inside the heart, it works as a one-way valve, allowing blood to flow from the left ventricle of the heart to the aorta, and preventing blood from flowing in the opposite direction. However, as described in greater detail below, some amount of blood may unintentionally flow in the opposite direction around the outside of the prosthetic heart valve due to PV leak.
In the illustrated embodiment, prosthetic heart valve 300 includes an expandable stent 302 with a plurality of CAFs 316 (only one illustrated in
Sealing members 320 may take the form of generally triangular patches of material, although other shapes may be suitable. The triangular patches may be attached to cuff 306 during valve assembly, or after valve assembly is otherwise complete. Any suitable attachment method, such as sewing, may be used. Preferably, a distal or open side 321 of each sealing member 320, in this case the distal side of the triangular patch, is left partially or completely unconnected to cuff 306. For example, if sewing the triangular patch to cuff 306, two proximal sides 322, 323 of the triangle, meeting at a proximalmost point, are sewn to the cuff, but the open side 321 of the triangle is not. With this configuration, the open side 321 of sealing member 320 remains capable of opening upon retrograde blood flow, with the open side facing the distal end of valve 300. Further, the closed proximal sides 322, 323 that are connected to cuff 306 restrict blood from exiting through the proximal sides of sealing member 320. Proximal sides 322, 323 may be sewn such that open side 321 is loose or floppy, and not taut, thereby enabling blood to flow into sealing member 320. As described above, if retrograde blood flow does occur on the abluminal side of valve 300, the parachuting or billowing action of sealing members 320 upon blood flowing into the sealing members facilitates active sealing between the prosthetic heart valve and the native tissue surrounding the valve.
When taking the form of triangular patches, sealing members 320 may be individual elements, as illustrated in
Alternatively, sealing members 320 may take the form of a plurality of triangular patches in series. Although
Each sealing member 320 may be attached to cuff 306, or to both the cuff and stent body 302. Preferably, each sealing member 320 is attached only to cuff 306 and is capable of parachuting or billowing open through a cell 312 of stent body 302 upon blood entering the sealing member. By attaching sealing members 320 to cuff 306 only, rather than to both the cuff and stent body 302, the overall bulkiness and/or profile of valve 300 may be reduced.
For this and other embodiments described herein, it should also be noted that sealing members 320, when valve 300 is implanted in a patient, may be situated sub-annularly, intra-annularly, and/or supra-annularly. The particular position of sealing members 320 with respect to the native annulus may be affected by, for example, the particular position of the sealing members on stent body 302. There may be particular advantages and disadvantages of each position. For example, if the sealing members are positioned supra-annularly, they may be less likely to be distorted by the shape of the native annulus. However, this positioning may be more likely to result in coronary blockage, a larger profile in a relatively bulky area of the valve, and the positioning may be coincident with the most calcified areas of the native anatomy. If the sealing members are positioned intra-annularly, they may provide for sealing above and below the annulus without causing other physiological issues. However, this positioning may lead to interference with anchoring features of a prosthetic valve, which may lead to a higher likelihood of valve migration or a larger profile in a relatively bulky area of the valve. Finally, if the sealing members are positioned sub-annularly, the valve may have a relatively small profile and the sealing members may be coincident with the least calcified portions of the native anatomy. However, this positioning may increase the likelihood of mitral valve or conduction interference, may require a longer delivery device and may result in a decreased tracking ability of the valve.
A number of variables may be manipulated to change the way in which, and how much, each sealing member 320 billows open during retrograde blood flow. For example, the type of material forming sealing member 320 may influence how it billows open. In particular, forming sealing member 320 from a material with high compliance, such as tissue, including bovine or porcine tissue, may cause the sealing member to open to a greater extent upon retrograde blood flow in comparison to a lower compliance material. Similarly, forming sealing member 320 from a thin material may lead the sealing member to open to a greater extent upon retrograde blood flow in comparison to a thicker material. The method of attaching sealing members 320 to valve 300 may also affect how the sealing members open. For example, loosely sewing sealing members 320 to cuff 306, such that the sealing members have a relatively large amount of slack, may lead the sealing members to open to a greater extent upon retrograde blood flow in comparison to a method in which the sealing members have relatively little slack from being sewn tightly to the cuff.
Still further, features such as orientation of fibers in the material used to form sealing members 320 may affect performance. For example, if sealing member 320 is formed from tissue and is attached to valve 300 with the fibers of the tissue oriented predominantly circumferentially, the fibers may have a spring-like effect and resist opening. This may result in relatively little billowing of sealing member 320 upon retrograde blood flow in comparison to a sealing member attached to the valve with tissue fibers oriented predominantly longitudinally. Regarding the fiber orientation,
Sealing member 320 may also take shapes other than generally triangular. For example,
The width of the open sides of the sealing members, such as open side 321 of sealing member 320, may also be varied. For example, the sealing members may have wider openings than those illustrated to maximize the likelihood of capturing retrograde blood flow. The wide openings, or any other sealing member openings described herein, may also alternately be punctuated by frequent stitches or other mechanisms to close portions of the open side. The effect of frequently spaced sutures, for example, may create a number of smaller openings that still allow blood flow to enter the particular sealing member. However, if a thrombus forms within the sealing member, the reduced sized openings may make it less likely that the thrombus may exit the sealing member into the blood flow.
Prosthetic heart valve 400 includes sealing members 420 that provide an active sealing mechanism for sealing against PV leak. Similar to valve 300, the sealing members 420 take the form of generally triangular patches or parachute-like members that billow open when blood flows into them. However, valve 400 includes proximal sealing members 420a positioned along the first row of cells 412a as well as distal sealing members 420b positioned along the second row of cells 412b. All of the considerations discussed above with respect to sealing members 320 of
As described with respect to sealing members 320, sealing members 420a, 420b may be individually attached to cuff 406, or multiple sealing members may first be connected to one another in a series for convenience. For example, in one embodiment, sealing members 420a, 420b may be attached to cuff 406 at each cell 412 in the first and second rows of cells 412a, 412b, respectively. Also as described with respect to sealing members 320, sealing members 420a, 420b may be placed strategically on valve 400 to maximize sealing against PV leak while minimizing the number of the sealing members, and therefore minimizing the bulk of the valve. One embodiment that may be particularly effective, illustrated in
A number of alternate configurations of sealing members may be utilized. As described above, sealing members, such as sealing members 420a and 420b, may be positioned on the inner diameter of stent body 402, that is, between the stent body and cuff 406. However, they may alternately be placed on the outer diameter of stent body 402. If positioned on the outer diameter, more shapes and configurations may be used since the sealing members no longer need to be capable of billowing open through the open cells of stent body 402. Rather, if on the outer diameter of stent body 402, the positions of open cells of stent body 402 do not limit the shape or configuration of the sealing members at all. For example,
Prosthetic heart valve 500 includes a sealing member 520 that provides an active sealing mechanism for sealing against PV leak. Sealing member 520 may take the form a rectangular patch that functions as a parachute-like member that billows open when blood flows into it. In the illustrated embodiment, sealing member 520 includes an open distal side 521 and a closed proximal side 522. The proximal side 522 of sealing member 520 may be attached, for example by sewing, to cuff 506. The attachment is preferably such that blood entering sealing member 520 cannot exit through the closed proximal side 522 of the sealing member. In this configuration, sealing member 520 defines a pocket. The pocket may include regions defined by the points at which sealing member 520 near the open side 521 is attached to cuff 506, as described below. Each region of the pocket may be in fluid communication with adjacent regions. The rectangular patch may be wrapped around the entire circumference of stent 502 with ends of the patch attached to one another to secure the patch in a desired position. In this embodiment, sealing member 520 is a separate entity from cuff 506. Further, in this embodiment, sealing member 520 is preferably attached over the outside of both cuff 506 and stent 502 to allow the sealing member to billow open. This is in contrast to other embodiments, such as generally triangular sealing members 320, which preferably are attached between cuff 306 and stent 302 and which are capable of billowing open through cells 312 of the stent.
One or more individual rectangular patches may be individually attached to stent 502 such that the collective patches are wrapped partially, or entirely, around the circumference of the stent. Portions of sealing member 520 near the open side 521 are also preferably attached to cuff 506, for example using sutures S. As illustrated, a small number of stitches, such as two or three, connect distal portions of sealing member 520 to cuff 506 at spaced locations around the circumference of the sealing member. While the sutures S are shown as attaching sealing member 520 to cuff 506 along portions of the struts where adjacent cells 512a meet, the connections may be made at any point on the cuff. The distal attachments preferably are few enough to leave a substantial portion of open side 521 free such that retrograde blood flow may freely flow into sealing member 520, while still providing enough support to maintain the position of the distal end of the sealing member relative to cuff 506. Similar to embodiments described above, if blood flows in the retrograde direction, represented by arrows DR, on the abluminal side of the valve 500, the blood may flow into sealing member 520 between the points at which the sealing member is attached to cuff 506. The blood may enter and fill sealing member 520, causing it to expand similar to an inner tube, facilitating the creation of a seal against PV leak between valve 500 and the native tissue in which the valve is positioned.
Sealing member 520 may alternately be formed as an extension of cuff 506, rather than one or more separate rectangular patches. For example, cuff 506, which is positioned on the luminal side of valve 500, may include a portion which extends beyond the proximal end of stent 502. This extending portion may be folded or wrapped around the proximal end of stent 502 such that the extending portion is on the abluminal side of valve 500. The extending portion would form sealing member 520 and would otherwise act similarly to separate rectangular patches attached to cuff 506. In this embodiment, in which sealing member 520 is an extension of cuff 506, it may not be necessary to suture or otherwise attach the proximal end of the sealing member to the cuff, since the sealing member is an extension of the cuff. However, it still may be preferable to form a seam, for example with a suture, between sealing member 520 and cuff 506 adjacent the proximal ends thereof. This may, for example, provide structural support to sealing member 520.
Each of the sections of stent 702 includes a plurality of cells 712 connected to one another in one or more annular rows around the stent. For example, as shown in
Prosthetic heart valve 700 includes sealing members 720a, 720b that provide an active sealing mechanism for sealing against PV leak. Sealing members 720a and 720b may each take a similar or identical form as sealing member 520 of prosthetic heart valve 500. For example, sealing member 720a may be a rectangular patch that functions as a parachute-like member that billows open when blood flows into it. In the illustrated embodiment, sealing member 720a includes an open distal side 721a and a closed proximal side 722a. The proximal side 722a of sealing member 720a may be attached, for example by sewing, to cuff 706. The attachment is preferably such that blood entering sealing member 720a cannot exit through the closed proximal side 722a of the sealing member. In this configuration, sealing member 720a defines a pocket. The pocket may include regions defined by the points at which sealing member 720a near the open side 721a is attached to cuff 706, as described below. Each region of the pocket may be in fluid communication with adjacent regions. The rectangular patch may be wrapped around the entire circumference of stent 702 with ends of the patch attached to one another to secure the patch in a desired position. In this embodiment, sealing member 720a is a separate entity from cuff 706. Further, in this embodiment, sealing member 720a is preferably attached over the outside of both cuff 706 and stent 702 to allow the sealing member to billow open.
Sealing member 720a may take the form of a single rectangular patch, or multiple patches connected to one another to form a rectangular patch that is long enough to extend around the entire circumference of annulus portion 740. Portions of sealing member 720a near the open side 721a are also preferably attached to cuff 706, for example using sutures 51. As illustrated, a small number of stitches, such as two or three, connect distal portions of sealing member 720a to cuff 706 at spaced locations around the circumference of the sealing member. In particular, the sutures 51 may be placed near where one cell 712a meets a circumferentially adjacent cell 712a, so that the pocket formed in sealing member 720a has a plurality of openings, each of which having a width substantially equal to a maximum circumferential width of a cell 712a when stent 702 is in the expanded condition. While the sutures 51 are shown as attaching sealing member 720a to cuff 706 along portions of the struts where adjacent cells 712a meet, the connections may alternatively be made at any point on the cuff. The distal attachments preferably are few enough to leave a substantial portion of open side 721a free such that retrograde blood flow may freely flow into sealing member 720a, while still providing enough support to maintain the position of the distal end of the sealing member relative to cuff 706.
Valve 700 may include a second sealing member 720b, which may take the form of a rectangular patch similar or identical to sealing member 720a (or similar to any described alternative way to form sealing member 720a). Sealing member 720b may be positioned mostly or entirely distal to sealing member 720a, so that a closed proximal side 722b of sealing member 720b is positioned adjacent to or spaced apart from the open distal side 721a of sealing member 720a. Closed proximal side 722b may be attached to cuff 706 with sutures or any other suitable fastening mechanism so that blood entering sealing member 720b from the open side 721b is unable to exit sealing member 720b through the closed side 722b. Similar to sealing member 720a, the open side 721b of sealing member 720b may be coupled to cuff 706 and/or struts of stent 702 at circumferentially spaced apart locations to form a plurality of openings leading into the pocket of sealing member 720b. In the illustrated embodiment, sutures S2 attach portions of the distal side of sealing member 720b at locations of cuff 706 and/or stent 702 at which a cell 712b in the second circumferential row meets a circumferentially adjacent cell 712b in that same row. With this configuration, the openings in open side 721b of sealing member 720b generally correspond to the maximum width of a cell 712b in the expanded condition of stent 702. This allows for circumferential positional staggering of the openings in the open side 721b of sealing member 720b compared to the openings in the open side 721a of sealing member 720a.
Similar to embodiments described above, if blood flows in the retrograde direction, represented by arrows DR, on the abluminal side of valve 700, the blood may flow into sealing member 720a between the points at which the sealing member is attached to cuff 706. The blood may enter and fill sealing member 720, causing it to expand similar to an inner tube, facilitating the creation of a seal against PV leak between valve 700 and the native tissue in which the valve is positioned. To the extent that retrograde blood flow is less likely to enter sealing member 720a at the positions at which open side 721a is sutured to the cuff 706 and/or stent 702, such retrograde blood flow may be likely to enter sealing member 720b since the corresponding locations of open side 721b of sealing member 720b will be free to open and receive retrograde blood flow. In other words, the use of two sealing members 720a-b with the attachment locations described above may provide for similar additional capability of mitigating PV leak as described in connection with the circumferentially staggered patches 421a-b of
Similar to sealing member 520, first sealing member 720a may alternately be formed as an extension of cuff 706, with cuff 706 including a portion which extends beyond the inflow edge of stent 702. This extending portion may be folded or wrapped around the inflow edge of stent 702 such that the extending portion is on the abluminal side of valve 700. The extending portion would form first sealing member 720 and would otherwise act similarly to a rectangular patch attached to cuff 706. In this embodiment, in which first sealing member 720a is an extension of cuff 706, it may not be necessary to suture or otherwise attach the proximal end of the first sealing member 720a to the cuff 706, since the sealing member is an extension of the cuff. However, it still may be preferable to form a seam, for example with a suture, between first sealing member 720a and cuff 706 adjacent the proximal ends thereof. This may, for example, provide structural support to first sealing member 720a.
Still further, first sealing member 720a and/or second sealing member 720b may be configured to wrap around only a part of the circumference of stent 702. This may allow, for example, strategic placement of sealing members 720a and/or 720b to maximize the likelihood of the sealing members 720a and/or 720b receiving retrograde blood flow while minimizing the amount of material and bulk added to valve 700. In one example of this, similar to the embodiment described in connection with
According to one aspect of the disclosure, a prosthetic heart valve comprises:
Although the prosthetic valves herein have been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.
The present application is a divisional of U.S. patent application Ser. No. 15/882,269, filed Jan. 29, 2018, and issued as U.S. Pat. No. 10,849,740 on Dec. 1, 2020, which is a continuation of U.S. patent application Ser. No. 15/148,322, filed May 6, 2016 and issued as U.S. Pat. No. 9,913,715 on Mar. 13, 2018, which is a continuation-in-part of U.S. patent application Ser. No. 14/501,200 filed Sep. 30, 2014 and issued as U.S. Pat. No. 9,668,857 on Jun. 6, 2017, which claims the benefit of the filing date of U.S. Provisional Patent Application No. 61/900,475 filed Nov. 6, 2013, the disclosures of which are all hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3409013 | Berry | Nov 1968 | A |
3467102 | Fogarty et al. | Sep 1969 | A |
3548417 | Kischer | Dec 1970 | A |
3587115 | Shiley | Jun 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Edwards et al. | Feb 1973 | A |
3755823 | Hancock | Sep 1973 | A |
3983581 | Angell et al. | Oct 1976 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4275469 | Gabbay | Jun 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4373216 | Klawitter | Feb 1983 | A |
4406022 | Roy | Sep 1983 | A |
4470157 | Love | Sep 1984 | A |
4491986 | Gabbay | Jan 1985 | A |
4535483 | Klawitter et al. | Aug 1985 | A |
4574803 | Storz | Mar 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4605407 | Black et al. | Aug 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4643732 | Pietsch et al. | Feb 1987 | A |
4655771 | Wallsten | Apr 1987 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4797901 | Goerne et al. | Jan 1989 | A |
4829990 | Thuroff et al. | May 1989 | A |
4851001 | Taheri | Jul 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4922905 | Strecker | May 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5037434 | Lane | Aug 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5080668 | Bolz et al. | Jan 1992 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5192297 | Hull | Mar 1993 | A |
5258023 | Reger | Nov 1993 | A |
5266073 | Wall | Nov 1993 | A |
5282847 | Trescony et al. | Feb 1994 | A |
5295958 | Shturman | Mar 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5360444 | Kusuhara | Nov 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411055 | Kane | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415664 | Pinchuk | May 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5480424 | Cox | Jan 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5549665 | Vesely et al. | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5571175 | Vanney et al. | Nov 1996 | A |
5591185 | Kilmer et al. | Jan 1997 | A |
5607464 | Trescony et al. | Mar 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5628786 | Banas et al. | May 1997 | A |
5639274 | Fischell et al. | Jun 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5716417 | Girard et al. | Feb 1998 | A |
5728068 | Leone et al. | Mar 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5776188 | Shepherd et al. | Jul 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5843161 | Solovay | Dec 1998 | A |
5843167 | Dwyer et al. | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5855602 | Angell | Jan 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5928281 | Huynh et al. | Jul 1999 | A |
5935163 | Gabbay | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6045576 | Starr et al. | Apr 2000 | A |
6077297 | Robinson et al. | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6090140 | Gabbay | Jul 2000 | A |
6110198 | Fogarty et al. | Aug 2000 | A |
6132473 | Williams et al. | Oct 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6174327 | Mertens et al. | Jan 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6214036 | Letendre et al. | Apr 2001 | B1 |
6217585 | Houser et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6231602 | Carpentier et al. | May 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6264691 | Gabbay | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6306164 | Kujawski | Oct 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6352554 | De Paulis | Mar 2002 | B2 |
6368348 | Gabbay | Apr 2002 | B1 |
6419695 | Gabbay | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468660 | Ogle et al. | Oct 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6488702 | Besselink | Dec 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6517576 | Gabbay | Feb 2003 | B2 |
6533810 | Hankh et al. | Mar 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6582464 | Gabbay | Jun 2003 | B2 |
6605112 | Moll et al. | Aug 2003 | B1 |
6610088 | Gabbay | Aug 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6685625 | Gabbay | Feb 2004 | B2 |
6716244 | Klaco | Apr 2004 | B2 |
6719789 | Cox | Apr 2004 | B2 |
6729356 | Baker et al. | May 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6780510 | Ogle et al. | Aug 2004 | B2 |
6783556 | Gabbay | Aug 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6814754 | Greenhalgh | Nov 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6837902 | Nguyen et al. | Jan 2005 | B2 |
6860901 | Baker et al. | Mar 2005 | B1 |
6869444 | Gabbay | Mar 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6911040 | Johnson et al. | Jun 2005 | B2 |
6951573 | Dilling | Oct 2005 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7137184 | Schreck | Nov 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7160322 | Gabbay | Jan 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7247167 | Gabbay | Jul 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7264632 | Wright et al. | Sep 2007 | B2 |
7267686 | DiMatteo et al. | Sep 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7320704 | Lashinski et al. | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7374573 | Gabbay | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7399315 | Iobbi | Jul 2008 | B2 |
7452371 | Pavcnik | Nov 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7585321 | Cribier | Sep 2009 | B2 |
7597711 | Drews et al. | Oct 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7731742 | Schlick et al. | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7871435 | Carpentier et al. | Jan 2011 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7951197 | Lane et al. | May 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7959674 | Shu et al. | Jun 2011 | B2 |
7967857 | Lane | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
D648854 | Braido | Nov 2011 | S |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8075611 | Millwee et al. | Dec 2011 | B2 |
8083793 | Lane et al. | Dec 2011 | B2 |
D652926 | Braido | Jan 2012 | S |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
D653342 | Braido et al. | Jan 2012 | S |
D653343 | Ness et al. | Jan 2012 | S |
D654169 | Braido | Feb 2012 | S |
D654170 | Braido et al. | Feb 2012 | S |
8137398 | Tuval et al. | Mar 2012 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
D660432 | Braido | May 2012 | S |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8182528 | Salahieh et al. | May 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8230717 | Matonick | Jul 2012 | B2 |
8231670 | Salahieh | Jul 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8308798 | Pintor et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8323336 | Hill et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8348998 | Pintor et al. | Jan 2013 | B2 |
8349000 | Schreck | Jan 2013 | B2 |
8366769 | Huynh et al. | Feb 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8408214 | Spenser | Apr 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8425593 | Braido et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449604 | Moaddeb et al. | May 2013 | B2 |
D684692 | Braido | Jun 2013 | S |
8454685 | Hariton et al. | Jun 2013 | B2 |
8454686 | Alkhatib | Jun 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8512396 | Styrc | Aug 2013 | B2 |
8568474 | Yeung et al. | Oct 2013 | B2 |
8579962 | Salahieh et al. | Nov 2013 | B2 |
8579966 | Seguin et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8591575 | Cribier | Nov 2013 | B2 |
8597349 | Alkhatib | Dec 2013 | B2 |
8603159 | Seguin et al. | Dec 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8613765 | Bonhoeffer et al. | Dec 2013 | B2 |
8623074 | Ryan | Jan 2014 | B2 |
8652204 | Quill et al. | Feb 2014 | B2 |
8663322 | Keranen | Mar 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8673000 | Tabor et al. | Mar 2014 | B2 |
8685080 | White | Apr 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8764820 | Dehdashtian et al. | Jul 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8795357 | Yohanan | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8834563 | Righini | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8845721 | Braido et al. | Sep 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8940040 | Shahriari | Jan 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8974523 | Thill et al. | Mar 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
9393110 | Levi et al. | Jul 2016 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010041928 | Pavcnik et al. | Nov 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020036220 | Gabbay | Mar 2002 | A1 |
20020173842 | Buchanan | Nov 2002 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030100939 | Yodfat et al. | May 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20030236567 | Elliot | Dec 2003 | A1 |
20030236568 | Hojeibane et al. | Dec 2003 | A1 |
20040033364 | Spiridigliozzi et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040082989 | Cook et al. | Apr 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040111111 | Lin | Jun 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050075718 | Nguyen et al. | Apr 2005 | A1 |
20050075725 | Rowe | Apr 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137695 | Salahieh | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050203605 | Dolan | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060004442 | Spenser et al. | Jan 2006 | A1 |
20060008497 | Gabbay | Jan 2006 | A1 |
20060025855 | Lashinski et al. | Feb 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
20060173532 | Flagle et al. | Aug 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195180 | Kheradvar et al. | Aug 2006 | A1 |
20060195186 | Drews et al. | Aug 2006 | A1 |
20060206202 | Bonhoeffer et al. | Sep 2006 | A1 |
20060229719 | Marquez et al. | Oct 2006 | A1 |
20060241744 | Beith | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259120 | Vongphakdy et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060276813 | Greenberg | Dec 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070016285 | Lane et al. | Jan 2007 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070067029 | Gabbay | Mar 2007 | A1 |
20070073387 | Forster et al. | Mar 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070100435 | Case et al. | May 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070239265 | Birdsall | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244552 | Salahieh et al. | Oct 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080039934 | Styrc | Feb 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080077236 | Letac et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080114452 | Gabbay | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080208327 | Rowe | Aug 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080243246 | Ryan et al. | Oct 2008 | A1 |
20080255662 | Stacchino et al. | Oct 2008 | A1 |
20080262602 | Wilk et al. | Oct 2008 | A1 |
20080269879 | Sathe et al. | Oct 2008 | A1 |
20090099653 | Suri et al. | Apr 2009 | A1 |
20090112309 | Jaramillo et al. | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090192599 | Lane et al. | Jul 2009 | A1 |
20090264997 | Salahieh et al. | Oct 2009 | A1 |
20090276027 | Glynn | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100036484 | Hariton et al. | Feb 2010 | A1 |
20100049306 | House et al. | Feb 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100087907 | Lattouf | Apr 2010 | A1 |
20100100176 | Elizondo et al. | Apr 2010 | A1 |
20100131055 | Case et al. | May 2010 | A1 |
20100168778 | Braido | Jul 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100204785 | Alkhatib | Aug 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100262231 | Tuval et al. | Oct 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20110022157 | Essinger et al. | Jan 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110098800 | Braido et al. | Apr 2011 | A1 |
20110098802 | Braido | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20110282439 | Thill et al. | Nov 2011 | A1 |
20110301692 | Seguin | Dec 2011 | A1 |
20110319988 | Schankereli et al. | Dec 2011 | A1 |
20120035719 | Forster et al. | Feb 2012 | A1 |
20120035722 | Tuval | Feb 2012 | A1 |
20120046742 | Tuval et al. | Feb 2012 | A1 |
20120078347 | Braido et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120083878 | Sequin et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120232646 | Agathos | Sep 2012 | A1 |
20120277856 | Spenser et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120303116 | Gorman, III et al. | Nov 2012 | A1 |
20120316642 | Yu et al. | Dec 2012 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130023984 | Conklin | Jan 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130190857 | Mitra et al. | Jul 2013 | A1 |
20130204359 | Thubrikar et al. | Aug 2013 | A1 |
20130211508 | Lane et al. | Aug 2013 | A1 |
20130218267 | Braido et al. | Aug 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130274873 | Delaloye | Oct 2013 | A1 |
20130338765 | Braido et al. | Dec 2013 | A1 |
20140046433 | Kovalsky | Feb 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140142694 | Tabor et al. | May 2014 | A1 |
20140155997 | Braido | Jun 2014 | A1 |
20140194981 | Menk | Jul 2014 | A1 |
20140214159 | Vidlund et al. | Jul 2014 | A1 |
20140222144 | Eberhardt et al. | Aug 2014 | A1 |
20140228946 | Chau et al. | Aug 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350663 | Braido et al. | Nov 2014 | A1 |
20140350665 | Braido et al. | Nov 2014 | A1 |
20140350667 | Braido et al. | Nov 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20140350669 | Gillespie et al. | Nov 2014 | A1 |
20160324633 | Gross et al. | Nov 2016 | A1 |
20170020696 | White | Jan 2017 | A1 |
Number | Date | Country |
---|---|---|
2246526 | Mar 1973 | DE |
19532846 | Mar 1997 | DE |
19546692 | Jun 1997 | DE |
19857887 | Jul 2000 | DE |
19907646 | Aug 2000 | DE |
10049812 | Apr 2002 | DE |
10049813 | Apr 2002 | DE |
10049814 | Apr 2002 | DE |
10049815 | Apr 2002 | DE |
10121210 | Nov 2002 | DE |
102005003632 | Aug 2006 | DE |
202008009610 | Dec 2008 | DE |
0103546 | Mar 1984 | EP |
0144167 | Jun 1985 | EP |
0592410 | Apr 1994 | EP |
0850607 | Jul 1998 | EP |
0597967 | Dec 1999 | EP |
1000590 | May 2000 | EP |
1057460 | Dec 2000 | EP |
1088529 | Apr 2001 | EP |
1360942 | Nov 2003 | EP |
1570809 | Sep 2005 | EP |
1584306 | Oct 2005 | EP |
1598031 | Nov 2005 | EP |
1926455 | Jun 2008 | EP |
2047824 | Apr 2009 | EP |
2059192 | May 2009 | EP |
2254513 | Dec 2010 | EP |
2537487 | Dec 2012 | EP |
2620125 | Jul 2013 | EP |
2749254 | Jul 2014 | EP |
2815725 | Dec 2014 | EP |
2870946 | May 2015 | EP |
2788217 | Jul 2000 | FR |
2850008 | Jul 2004 | FR |
2847800 | Oct 2005 | FR |
2056023 | Mar 1981 | GB |
2008541865 | Nov 2008 | JP |
2011500241 | Jan 2011 | JP |
2011522634 | Aug 2011 | JP |
2011528256 | Nov 2011 | JP |
2012504031 | Feb 2012 | JP |
158988 | Nov 1963 | SU |
1271508 | Nov 1986 | SU |
1371700 | Feb 1988 | SU |
1457921 | Feb 1989 | SU |
9117720 | Nov 1991 | WO |
9217118 | Oct 1992 | WO |
9301768 | Feb 1993 | WO |
9716133 | May 1997 | WO |
9724080 | Jul 1997 | WO |
9832412 | Jul 1998 | WO |
199829057 | Jul 1998 | WO |
9913801 | Mar 1999 | WO |
9933414 | Jul 1999 | WO |
9940964 | Aug 1999 | WO |
9947075 | Sep 1999 | WO |
2000018333 | Apr 2000 | WO |
200041652 | Jul 2000 | WO |
200047139 | Aug 2000 | WO |
0128459 | Apr 2001 | WO |
2001035878 | May 2001 | WO |
200149213 | Jul 2001 | WO |
0154625 | Aug 2001 | WO |
0156500 | Aug 2001 | WO |
200162189 | Aug 2001 | WO |
2001054624 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0166035 | Sep 2001 | WO |
0166037 | Sep 2001 | WO |
2001076510 | Oct 2001 | WO |
2002022054 | Mar 2002 | WO |
0236048 | May 2002 | WO |
2002041789 | May 2002 | WO |
0247575 | Jun 2002 | WO |
2002043620 | Jun 2002 | WO |
2002049540 | Jun 2002 | WO |
02067782 | Sep 2002 | WO |
03037222 | May 2003 | WO |
03047468 | Jun 2003 | WO |
2003075799 | Sep 2003 | WO |
2004016200 | Feb 2004 | WO |
2005062980 | Jul 2005 | WO |
2005070343 | Aug 2005 | WO |
2005087140 | Sep 2005 | WO |
2006014233 | Feb 2006 | WO |
2006034008 | Mar 2006 | WO |
06073626 | Jul 2006 | WO |
2006124649 | Nov 2006 | WO |
2006127765 | Nov 2006 | WO |
2006128193 | Nov 2006 | WO |
2007053243 | May 2007 | WO |
07071436 | Jun 2007 | WO |
2008005405 | Jan 2008 | WO |
2008035337 | Mar 2008 | WO |
08070797 | Jun 2008 | WO |
2008100600 | Aug 2008 | WO |
2008147964 | Dec 2008 | WO |
2008150529 | Dec 2008 | WO |
2009024859 | Feb 2009 | WO |
2009042196 | Apr 2009 | WO |
2009045338 | Apr 2009 | WO |
2009053497 | Apr 2009 | WO |
2009061389 | May 2009 | WO |
2009149462 | Dec 2009 | WO |
2010008548 | Jan 2010 | WO |
2010008549 | Jan 2010 | WO |
2010037141 | Apr 2010 | WO |
2010096176 | Aug 2010 | WO |
2010098857 | Sep 2010 | WO |
2010141847 | Dec 2010 | WO |
2011057087 | May 2011 | WO |
2011133787 | Oct 2011 | WO |
2012032187 | Mar 2012 | WO |
2012048035 | Apr 2012 | WO |
2012161786 | Nov 2012 | WO |
2012177942 | Dec 2012 | WO |
2014110171 | Jul 2014 | WO |
Entry |
---|
“Closed heart surgery: Back to the future”, Samuel V. Lichtenstein, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, pp. 941-943; May 2006. |
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005). |
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Apr. 24, 2006). |
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006). |
“Transapical Aortic Valve Implantation: An Animal Feasibility Study”, Todd M. Dewey et al., The Annals of Thoracic Surgery, 2006, 82: 110-6 (Feb. 13, 2006). |
“Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”; Th. Walther et al., European Journal of Cardio-thoracic Surgery 29 (2006) 703-708 (Jan. 30, 2006). |
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al., Circulation.2006; 114: 591-596 (Jul. 31, 2006). |
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenosis,” British Heart Journal, Jan. 1987, vol. 57. No. 1, pp. 51-53. |
Al-Khaja, N., et al., “Eleven Years′ Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery 3:305-311, Jun. 30, 2009. |
Almagor, Y. et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, Nov. 1, 1990, 16(6):1310-1314. |
Andersen, H. R., “History of Percutaneous Aortic Valve Prosthesis,” Herz, Aug. 2009, 34(5):343-346. |
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves,” European Heart Journal, May 1992, pp. 704-708, vol. 13, No. 5. |
Andersen, H.R., “Transluminal Catheter Implanted Prosthetic Heart Valves,” International Journal of Angiology, Mar. 1998, pp. 102-106, vol. 7, No. 2. |
Benchimol, Alberto, et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977 vol. 273, No. 1, pp. 55-62. |
Buellesfeld, et al., “Treatment of paravalvular leaks through inverventional techniques,” Multimed Man Cardiothorac Surg., Department of Cardiology, Ben University Hospital, pp. 1-8, Jan. 2011. |
Bullesfeld et al., Percutaneous Implantation of The First Repositionable Aortic Valve Prosthesis in a Patient With Severe Aortic Stenosis, Catheterization & Cardiovascular Interventions 71:579-84 (2008). |
Catheter-implanted prosthetic heart valves, Knudsen, L.L., et al., The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262. |
Curriculum Vitae of Robert A. Ersek, M.D., FACS, Jul. 10, 2009, http://www.ersek.com/rae-cv.htm. |
De Cicco, et al., “Aortic valve periprosthetic leakage: anatomic observations and surgical results,” The Annals of thoracic surgery, vol. 79, No. 5, pp. 1480-1485, May 2005. |
Dotter, C. T. et al., “Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of its Application,” Circulation, Nov. 1964, 30:654-670. |
European Communication for Application No. 09788918.2 dated Jun. 29, 2015. |
European Search Report for Application No. 14186568.3 dated Mar. 6, 2015. |
Extended European Search Report for Application No. 14180622.4 dated Nov. 21, 2014. |
Extended European Search Report for Application No. 14180623.2 dated Nov. 24, 2014. |
Extended European Search Report for Application No. 14180625.7 dated Nov. 24, 2014. |
Gössl, Mario, and Charanjit S. Rihal. “Percutaneous treatment of aortic and mitral valve paravalvular regurgitation.” Current cardiology reports 15.8 (2013). |
Gössl,et al., “Percutaneous treatment of aortic and mitral valve paravalvular regurgitation,” Current Cardiology Reports, vol. 15, No. 8., pp. 1-8, Aug. 2013. |
Grube et al., “Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease” (2006). |
Heart Advisor, “Heart repairs without surgery. Minimally invasive procedures aim to correct valve leakage,” Sep. 2004, pp. 4-5, PubMed ID 15586429. |
Hourihan, et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks,” Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, Nov. 1992. |
Inoune, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984. |
International Search Report and Written Opinion PCT/US2014/020872 dated Mar. 19, 2014. |
International Search Report from corresponding PCT application No. PCT/US2011/054973 dated Apr. 23, 2012. |
International Search Report PCT/US2009/004094 dated Mar. 3, 2010. |
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008. |
Knudsen, L.L. et al., “Catheter-implanted prosthetic heart valves,” The International Journal of Artificial Organs, May 1993, pp. 253-262, vol. 16, No. 5. |
Kolata, Gina, “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” nytimes.com, http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteri- es-gets-a-faili . . . , Jul. 29, 2009, 2 pages. |
Lawrence, Jr., M.D., David D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology 1897; 163: 357-360. |
Moazami, N. et al., “Transluminal Aortic Valve Placement,” ASAIO Journal, Sep./Oct. 1996, pp. M381-M385, vol. 42. |
Muñoz, et al., “Guidance of treatment of perivalvular prosthetic leaks.”, Current cardiology reports, 16.430, 6 pages, Jan. 2014. |
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154. |
Percutaneous aortic valve replacement: resection before implantation, 836-840, Quaden, Rene et al., European J. of Cardio-thoracic Surgery, 27 (2005). |
Porstmann, W., et al., “Der Verschlu.beta. des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskulare Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203, English translation of Abstract only. |
Quaden, R. et al., “Percutaneous aortic valve replacement: resection before implantation,” European J. of Cardio-thoracic Surgery, May 2005, pp. 836-840, vol. 27, No. 5. |
Rashkind, M.D., William J., “Creationof an Atrial Septal Defect Withoput Thoracotomy,” the Journal of the American Medical Association, vol. 196, No. 11, Jun. 13, 1966, pp. 173-174. |
Rashkind, W. J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Dec. 1986, 13(4):363-367. |
Rohde,et al., “Resection of Calcified Aortic Heart Leaflets In Vitro by Q-Switched 2 μm Microsecond Laser Radiation”, Journal of Cardiac Surgery, 30(2):157-62. Feb. 2015. |
Rosch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radiol 2003; 14:841-853. |
Ross, F.R.C.S., D.N., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, Jan. 1968. |
Ruiz, C., “Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies,” Euro PCR, May 2010 (Powerpoint dated May 25, 2010). |
Sabbah, A. N. et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Dec. 1989, Journal of Cardiac Surgery, 4(4):302-309. |
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538. |
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989. |
Sigwart, U., “An Overview of Intravascular Stents: Old and New,” Chapter 48, Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815. |
Swiatkiewicz, et al., “Percutaneous closure of mitral perivalvular leak,” Kardiologia Polska, vol. 67, No. 7, pp. 762-764, Jul. 2009. |
Textbook “Transcatheter Valve Repair”, 2006, pp. 165-186. |
Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks, Hourihan et al., Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, (1992). |
Transluminal Catheter Implanted Prosthetic Heart Valves, Andersen, Henning Rud, International Journal of Angiology 7:102-106 (1998). |
Transluminal implantation of artificial heart valves, Andersen, H. R., et al., European Heart Journal (1992) 13, 704-708. |
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187. |
Urban, M.D., Philip, “Coronary Artery Stenting,” Editions Medecine et Hygiene, Geneve, 1991, pp. 5-47. |
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, 227-230. |
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, Butterworths 1986. |
Zegdi, R., MD, PhD et al., “Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?” J. of the American College of Cardiology, Feb. 5, 2008, pp. 579-584, vol. 51, No. 5. |
Number | Date | Country | |
---|---|---|---|
20210007843 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
61900475 | Nov 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15882269 | Jan 2018 | US |
Child | 17030464 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15148322 | May 2016 | US |
Child | 15882269 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14501200 | Sep 2014 | US |
Child | 15148322 | US |